<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01096745</url>
  </required_header>
  <id_info>
    <org_study_id>GNUHIRB-2010-5</org_study_id>
    <nct_id>NCT01096745</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Gemcitabine/Cisplatin Versus S-1/Cisplatin in Advanced Biliary Cancer</brief_title>
  <official_title>Randomized Phase II Trial of Gemcitabine/Cisplatin Versus S-1/Cisplatin in Advanced Biliary Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gyeongsang National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dong-A University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chung-Ang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gyeongsang National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy between gemcitabine/cisplatin and
      S-1/cisplatin in the first-line treatment in advanced biliary tract cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard chemotherapy regimen for biliary tract cancer(BTC) has not been established due to
      the difficulty associated with performing clinical trials in this field.

      Gemcitabine or fluoropyrimidines, including 5-fluorouracil and S-1, are routinely used for
      BTC chemotherapy. The European Society for Medical Oncology (ESMO) and the National
      Comprehensive Cancer Network guidelines published in 2009 recommend either gemcitabine-based
      or fluoropyrimidine-based chemotherapy or clinical trials for first-line treatment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Planning for randomized phase III trial for this issue.
  </why_stopped>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>From the assigned day to the disease progression or the last day of follow-up without progression. Clinically assessment would be done every cycle (month) and radiologically assessed every 6 weeks with CT scan</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate Overall survival Safety profile</measure>
    <time_frame>Overall survival is measured from the first day of assignment until death or the last day of the follow-up.Clinically assessment would be done every cycle (month) and radiologically assessed every 2 cycles (6 weeks) with CT scan</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Metastatic Biliary Tract Cancer</condition>
  <condition>Locally Advanced Biliary Tract Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine/Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>S-1/Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D1-14 S-1 40mg/m2 po bid D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins Repeated every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine, Cisplatin</intervention_name>
    <description>D1,D8 Gemcitabine 1000mg/m2 + N/S 150cc miv over 30mins D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins repeated every 3weeks</description>
    <arm_group_label>Gemcitabine/Cisplatin</arm_group_label>
    <other_name>Gemcitabine - Gemcitane</other_name>
    <other_name>Cisplatin - Cispulan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1, Cisplatin</intervention_name>
    <description>D1-14 S-1 40mg/m2 po bid D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins Repeated every 3 weeks</description>
    <arm_group_label>S-1/Cisplatin</arm_group_label>
    <other_name>S-1; TS-1</other_name>
    <other_name>Cisplatin ; Cispulan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age : older than 20

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 -2

          -  Histologically confirmed adenocarcinoma of the biliary tract

          -  Metastatic or unresectable biliary cancer

          -  No prior chemotherapy for biliary cancer

          -  A patient with at least one measurable primary lesion of which the diameter is
             confirmed to be 10mm in Spiral CT or multidetector CT (MD CT)

          -  Adequate bone marrow, liver, renal function

        Exclusion Criteria:

          -  A patient with no measurable disease

          -  A patient who received previous palliative chemotherapy for biliary cancer

          -  A patient who received adjuvant chemotherapy for biliary cancer within 1year

          -  A patient with previous active or passive immunotherapy.

          -  A pregnant or lactating patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyuk-Chan Kwon, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dong-A University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jung Hun Kang, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Gyeongsang University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gyeongsang University Hospital</name>
      <address>
        <city>Jinju</city>
        <state>Gyeongsang Namdo</state>
        <zip>660-702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2010</study_first_submitted>
  <study_first_submitted_qc>March 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2010</study_first_posted>
  <last_update_submitted>June 21, 2011</last_update_submitted>
  <last_update_submitted_qc>June 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jung Hun Kang/Assisstant Professor</name_title>
    <organization>Gyeongsang National University Hospital</organization>
  </responsible_party>
  <keyword>Gemcitabine</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>S-1</keyword>
  <keyword>bile duct cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

